Data as of Sep 13, 2026. Both funds on the fields they both publish, from the same sources.
VB vs XBI: how they differ
VB and XBI hold 0% of their weight in the same names, and XBI returned more over the year.
Vanguard Small-Cap Index Fund and State Street(R) SPDR(R) S&P(R) Biotech ETF.
What they hold in common
By the books each fund has filed, VB and XBI hold 0% of their money in the same securities at the same weight.
| Only in VB | Only in XBI |
|---|---|
| Credo Technology Group Holding Ltd 0.55% | MODERNA INC 2.87% |
| Jabil Inc 0.49% | TWIST BIOSCIENCE CORP 1.81% |
| REVOLUTION Medicines Inc 0.46% | HALOZYME THERAPEUTICS INC 1.47% |
| Astera Labs Inc 0.45% | NATERA INC 1.46% |
| Natera Inc 0.45% | KYMERA THERAPEUTICS INC 1.45% |
| EMCOR Group Inc 0.45% | TRAVERE THERAPEUTICS INC 1.40% |
| Twilio Inc 0.38% | ROIVANT SCIENCES LTD 1.39% |
| NRG Energy Inc 0.38% | ORUKA THERAPEUTICS INC 1.38% |
Weight overlap is an ETFIQ calculation: for every security both funds hold, the smaller of the two weights, summed. Above 50%, holding both is close to holding one of them twice. Holdings dated Jun 30, 2026 and Sep 10, 2026.
| VB Vanguard Small-Cap Index Fund | XBI State Street(R) SPDR(R) S&P(R) Biotech ETF | |
|---|---|---|
| Where it sits | Core index fund | Core index fund |
| Issuer | Vanguard | State Street |
| What it is | Small-Cap | SPDR S&P Biotech |
| Total return, 1 year | +15.2% | +64.0% |
| S&P 500 over the same days | +17.5% | +17.5% |
| Gap to the S&P 500 | −2.3 pts | +46.5 pts |
| Expense ratio | 0.03% | 0.35% |
| Already in the S&P 500 | 21.7% | 8.5% |
| Holdings | 1311 | 154 |
VB in plain words
VB is an index equity fund tracking the Small-Cap. Over the year to Sep 11, 2026 it returned +15.2% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.03% a year. By its holdings filed for Jun 30, 2026, 22% of the fund by weight is stocks the S&P 500 also holds, across 1311 positions, with the top ten at 4.3%. It sat 5.1% below its high of Aug 14, 2026 on Sep 11, 2026.
XBI in plain words
XBI is an index equity fund tracking the SPDR S&P Biotech. Over the year to Sep 11, 2026 it returned +64.0% with distributions reinvested, against +17.5% for the S&P 500 and +23.0% for the Nasdaq-100. The prospectus expense ratio is 0.35% a year. By its holdings filed for Sep 10, 2026, 8% of the fund by weight is stocks the S&P 500 also holds, across 154 positions, with the top ten at 15.9%. It sat 9.6% below its high of Feb 8, 2021 on Sep 11, 2026.
Questions people ask
- Which returned more over the last year, VB or XBI?
- In the year to Sep 13, 2026, with distributions reinvested, VB returned +15.2% and XBI returned +64.0%, so XBI returned more. One year is one year; the longer windows are in the table.
- Which is cheaper, VB or XBI?
- VB charges 0.03% a year and XBI charges 0.35%, so VB is cheaper. Fees come from each fund's prospectus.
- How much do VB and XBI overlap with the S&P 500?
- By their latest filed holdings, 22% of VB and 8% of XBI by weight is stocks the S&P 500 already holds. Between the two funds, 0% of their books are the same securities at the same weight.
Other comparisons
Where to next
Where these figures came from
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement.
Cite this page. ETFIQ, VB against XBI, data as of Sep 13, 2026. https://etfiq.com/compare/any/vb-vs-xbi Free to use with attribution; the underlying files are at Open data.
A comparison is not a recommendation. Standards and sources